Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome

BACKGROUND AND AIMS: Teduglutide, a GLP-2 analogue, may restore intestinal structural and functional integrity by promoting repair and growth of the mucosa and reducing gastric emptying and secretion, thereby increasing fluid and nutrient absorption in patients with short bowel syndrome (SBS). This...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeppesen, P B, Gilroy, R, Pertkiewicz, M, Allard, J P, Messing, B, O'Keefe, S J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Group 2011
Materias:
Small Bowel
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112364/
https://www.ncbi.nlm.nih.gov/pubmed/21317170
http://dx.doi.org/10.1136/gut.2010.218271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112364/
https://www.ncbi.nlm.nih.gov/pubmed/21317170
http://dx.doi.org/10.1136/gut.2010.218271

Ejemplares similares